Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q3 EPS of ($0.54), $0.29 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $374.55 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.